2022 STD Prevention Conference
Homepage Banner Graphic

Abstract Classification List

Gender (check all that apply)

No specific gender
Men
Women
Transgender
Not applicable

Age Group (check all that apply)

Adolescents (10-18 years)
Adults
Young Adults (19 – 24 years)
Other, including infants
Not applicable

Primary Population of Focus (select up to 3)

Clients of a community-based organization (excluding faith-based CBOs)
Clinic patients
Clinicians or other Health Care Providers
Community-based organization (CBO) staff
GBMSM (gay, bisexual, or other men who have sex with men)
GBWSW (gay, bisexual, or other women who have sex with women)
General population
Heterosexuals
HIV Prevention Providers
People who are experiencing homelessness.
Immigrants or Migrants
Legislators or other policymakers
Parents or other family members
People living with HIV/AIDS
People using injection drugs
People who use alcohol or other drugs (excluding people injecting drugs)
Pregnant Persons
Sex Workers
Other population
Not applicable

Geographic Area of the Study (check all that apply)

United States
Canada
Mexico
Caribbean (please specify the country or countries)
Central or South America (please specify the country or countries)
Other (please specify the country or countries)

Settings (select up to 3)

College or university
Community-based organization (exclusive of a faith community setting)
Faith community setting (e.g., church, mosque, or synagogue)
HIV care clinic
Jail or prison
Military settings
Other clinical settings
Primary or secondary school
Rural settings
STD/STI/Sexual health clinics
Suburban settings
Urban settings
Not applicable

Does this abstract describe the development, refinement, or validation of laboratory techniques?

Yes
No

Does this abstract describe an intervention?

Yes – an intervention with randomization of people or places and a control group (e.g., an RCT)
Yes – an intervention with a change in practice or policy and a comparison group (e.g., xxx).
Yes – an intervention with a change in practice or policy evaluated over time (e.g., a quality
improvement project).
No

Which diseases or infections are covered in the abstract? Diseases and infections (select up to 3).

Bacterial Vaginosis
Chlamydia
Gonorrhea
Herpes
Hepatitis
HIV
Human papillomavirus, including related sequelae
Lymphogranuloma venereum
Mycoplasma genitalium
Pelvic inflammatory disease
Syphilis, including congenital syphilis
Trichomoniasis
STDs/STIs /not specified
Other
Not applicable

Which of the following come closest to describing the most important general topics in the abstract (up to 2)?

A health communication or social marketing campaign
A law, regulation, or other policy
A specific intervention upon behaviors (patients, providers, or others)
Assessment of behaviors
Assessment of morbidity in a population or sub-population
Assessment of population health services or gaps in services
Costs, cost-effectiveness, or return on investment for an intervention or program practice
Other health systems’ practices or operations
Policy development, or the integration of policy, science, and program
Population-level impact of an intervention or program practice
STD program practices or operations
The clinical management of cases

Which analytic approaches are used in this abstract (select up to 2)?

Economic analyses (e.g., cost-effectiveness or return on investment)
Epidemiologic analyses
Mathematical modeling
Molecular diagnosis methods
Other evaluation analytic approaches
Other laboratory methods
Qualitative data analyses
Quality improvement analyses
Randomized controlled trial or other intervention outcome analyses
Survey analyses
Whole genome sequencing
Other quantitative approaches
Not applicable

Event Information

September 19-22, 2022
Virtual
All session times are Eastern Daylight Time.

Register

Important Dates

October 23, 2022
Continuing Education (CE) Submission Deadline

Questions?

For inquiries, please contact: stdconf@cdc.gov.